Left Atrial Effective Conducting Size Predicts Atrial Fibrillation Vulnerability in Persistent but Not Paroxysmal Atrial Fibrillation
Overview
Physiology
Authors
Affiliations
Background: The multiple wavelets and functional re-entry hypotheses are mechanistic theories to explain atrial fibrillation (AF). If valid, a chamber's ability to support AF should depend upon the left atrial size, conduction velocity (CV), and refractoriness. Measurement of these parameters could provide a new therapeutic target for AF. We investigated the relationship between left atrial effective conducting size (LA ), a function of area, CV and refractoriness, and AF vulnerability in patients undergoing AF ablation.
Methods And Results: Activation mapping was performed in patients with paroxysmal (n = 21) and persistent AF (n = 18) undergoing pulmonary vein isolation. Parameters used for calculating LA were: (a) left atrial body area (A); (b) effective refractory period (ERP); and (c) total activation time (T). Global CV was estimated as . Effective atrial conducting size was calculated as . Post ablation, AF inducibility testing was performed. The critical LA required for multiple wavelet termination was determined from computational modeling. LA was greater in patients with persistent vs paroxysmal AF (4.4 ± 2.0 cm vs 3.2 ± 1.4 cm; P = .049). AF was inducible in 14/39 patients. LA was greater in AF-inducible patients (4.4 ± 1.8 cm vs 3.3 ± 1.7 cm; P = .035, respectively). The difference in LA between inducible and noninducible patients was significant in patients with persistent (P = .0046) but not paroxysmal AF (P = .6359). Computational modeling confirmed that LA > 4 cm was required for continuation of AF.
Conclusions: LA measured post ablation was associated with AF inducibility in patients with persistent, but not paroxysmal AF. These data support a role for this method in electrical substrate assessment in AF patients.
Martinez Diaz P, Dasi A, Goetz C, Unger L, Haas A, Luik A Europace. 2024; 26(10).
PMID: 39177260 PMC: 11500604. DOI: 10.1093/europace/euae215.
Sakata K, Bradley R, Prakosa A, Yamamoto C, Ali S, Loeffler S Nat Cardiovasc Res. 2024; 3(7):857-868.
PMID: 39157719 PMC: 11329066. DOI: 10.1038/s44161-024-00489-x.
A Novel Workflow for Electrophysiology Studies in Patients with Brugada Syndrome.
Hartwig V, Morelli M, Martini N, Seghetti P, Tirabasso D, Positano V Sensors (Basel). 2024; 24(13).
PMID: 39001120 PMC: 11244551. DOI: 10.3390/s24134342.
Jin Z, Hwang T, Kim D, Lim B, Kwon O, Kim S NPJ Digit Med. 2024; 7(1):81.
PMID: 38532181 PMC: 10966060. DOI: 10.1038/s41746-024-01075-y.
Xu H, Williams S, Williams M, Newby D, Taylor J, Neji R Eur Heart J Cardiovasc Imaging. 2023; 24(5):607-615.
PMID: 36725705 PMC: 10125223. DOI: 10.1093/ehjci/jead010.